Dissolution Method Development — BCS Framework Applied to IND-to-NDA Method Selection

The dissolution method you choose at IND is almost never the dissolution method that survives to NDA. The IND method is selected for analytical simplicity. The NDA method is selected for clinical relevance.

The gap between these two methods is the IND-to-NDA dissolution method development program — and FDA chemistry reviewers who receive an NDA with an IND-era dissolution method that has never been evaluated for biorelevance or discriminating capability will ask exactly the questions the development team did not ask.

BCS Classification and Medium Selection — Dose/Solubility Volume Calculation, Sink Condition Verification, and the Scientific Argument That Justifies SDS or FaSSIF Over a Simple Compendial Buffer

The single calculation that determines whether a simple compendial buffer will actually work as a dissolution medium is the dose-to-solubility volume: the highest strength dose in milligrams divided by the API’s aqueous solubility at pH 6.8 in milligrams per milliliter, compared against a 250 milliliter threshold. An API dosed at 250 mg with an aqueous solubility of 0.05 mg/mL at pH 6.8 produces a dose/solubility volume of 5,000 mL, dramatically above the 250 mL threshold that separates high from low solubility — placing the compound squarely in BCS Class II territory and meaning a standard pH 6.8 phosphate buffer will not provide adequate sink conditions for a meaningful dissolution test. Sink condition verification makes this concrete: comparing the concentration the API would reach at full release against its actual solubility in the test medium, a ratio above roughly 3 means the medium is saturating before the tablet has fully released, and both a fast-releasing and a slow-releasing formulation will simply plateau at the same low percentage dissolved, making the method blind to exactly the difference it exists to detect. Adding a surfactant changes this picture directly: 0.5% sodium dodecyl sulfate in pH 6.8 phosphate buffer, sitting well above SDS’s critical micelle concentration, solubilizes the API through micellar action and can push the sink ratio back under the acceptable threshold, restoring the medium’s ability to discriminate. FaSSIF, built from bile salt and lecithin components to simulate the actual fasted-state intestinal environment, achieves a similar or greater solubility enhancement through the same micellar mechanism but with substantially more physiological relevance — and a defensible NDA medium selection compares both media directly on pilot batches before choosing SDS for its greater analytical simplicity in routine QC use, rather than defaulting to whichever medium was easiest to prepare.

Discrimination Capability and Method Optimization — Testing the Method Against the Formulation Variable That Actually Drives In Vivo Performance, Not Just Any Two Tablet Formulations

A dissolution method that shows a difference between a drug product tablet and a placebo tablet has proven almost nothing useful, because that comparison doesn’t test whether the method can distinguish formulations that differ in the way that actually matters clinically. The comparison that matters is between formulation variants that differ specifically in the parameter suspected to drive in vivo dissolution performance, a micronized API at a fine particle size against the same API left unmicronized at a substantially coarser size, for instance, and a properly optimized method needs to show a real, substantial gap in dissolved percentage between the two variants while a non-discriminating medium shows essentially no difference between them at all. This distinction is what separates a method that merely produces different numbers for different samples from one that’s actually earning its place as the quality control gate protecting bioavailability. Method optimization itself follows the same logic: rather than adding surfactant at a single concentration and calling the work done, a defensible development program compares dissolution profiles across a concentration range, confirming that the selected level is the point at which discrimination against the relevant formulation variable is actually achieved, not simply the point at which the numbers happen to look reasonable. A dissolution method development report presenting discrimination data against the wrong comparator, drug product versus placebo rather than optimized versus suboptimal formulation, has answered a question nobody asked while leaving the one that matters unaddressed.

IND-to-NDA Method Evolution and Specification Justification — Cross-Method Comparability Data, ICH Q2(R2) Validation, and the Q-Value Derivation From Bioequivalence Data

Because the IND dissolution method and the eventual NDA method are almost never identical for a BCS Class II or IV product, the 3.2.P.2 pharmaceutical development section carries an obligation that’s easy to overlook: documenting the transition between them with actual comparability data rather than simply presenting the NDA method as though it had always been in use. Running both the original IND method and the new NDA method side by side on the same pilot or Phase III confirmation batches, and showing that those batches meet both specifications simultaneously, closes a gap that would otherwise leave an FDA chemistry reviewer unable to confirm that the clinical material generating the pivotal bioequivalence or efficacy data would actually have passed the dissolution standard the NDA now proposes. Once the method itself is settled, ICH Q2(R2) validation has to cover the complete parameter set, specificity confirming no interference from tablet excipients, linearity across the label claim concentration range, accuracy and precision at multiple concentration levels, and critically, robustness testing showing the method’s results don’t shift meaningfully under small, realistic variations in agitation speed, pH, or temperature — a validation package that stops at accuracy and precision without robustness data leaves the reviewer unable to confirm the method will perform consistently as a routine QC test across ordinary day-to-day laboratory variation. The dissolution specification itself, ultimately, only carries regulatory weight once it’s traceable back to the bioequivalence study data that established what dissolution performance actually corresponds to acceptable in vivo behavior — a Q30 limit presented without that traceability is a number asserted, not a number derived.

The XGene IND-to-NDA Dissolution Method Development Architecture — BCS Classification, Biorelevant Medium Selection, Discrimination Capability, and the Complete FDA NDA Dissolution CMC Package

The XGene IND-to-NDA Dissolution Method Development Architecture is a structured dissolution method development and validation program built around the recognition that dissolution method selection is a regulatory argument, not a laboratory convenience.

1. BCS Classification Documentation — Establish aqueous solubility across the physiological pH range and calculate the dose/solubility volume to determine whether a simple compendial buffer will provide adequate sink conditions. 2. Biorelevant Medium Selection and Sink Verification — Compare SDS and FaSSIF performance directly, verify the sink condition ratio in the selected medium, and justify the final choice on discrimination and practicality grounds together. 3. Discrimination Capability Testing Against the Clinically Relevant Variable — Test the method against formulation variants differing in the specific parameter believed to drive in vivo performance, not against a placebo. 4. IND-to-NDA Cross-Method Comparability Bridge — Run both methods on the same pilot or Phase III batches to confirm the clinical material meets the NDA specification retroactively. 5. ICH Q2(R2) Validation and Specification Derivation — Complete the full validation parameter set including robustness, and trace the final Q-value back to the bioequivalence study dissolution data.

The output is the dissolution method development package that gives FDA chemistry reviewers the complete regulatory argument, BCS basis, discrimination evidence, and method continuity, that a dissolution specification needs to be accepted as more than an analytically convenient number.

FDA’s Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms (1997) establishes the standard dissolution conditions and discriminating ability requirement this article’s framework is built around, while the FDA BCS biowaiver guidance (2017 update) establishes the dose/solubility volume calculation and BCS classification criteria applied to medium selection. ICH Q2(R2) Validation of Analytical Procedures (2023) establishes the validation parameter set, including robustness, that a dissolution method must satisfy before supporting an NDA specification.

For your current NDA dissolution method, can you confirm today that your 3.2.P.2 pharmaceutical development section documents the BCS classification with the dose/solubility volume calculation, discrimination capability data against the actual formulation variable that drives in vivo performance, and cross-method comparability data bridging your IND specification to your NDA specification?